Ronac Mamtani, Msce

List of Publications by Year
in descending order

119 papers	5,819 citations	147801 31 h-index	82547 72 g-index
123 all docs	123 docs citations	123 times ranked	10058 citing authors

#	Article	IF	Citations
1	Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With <scp>Metaâ€Analysis</scp>. Arthritis Care and Research, 2023, 75, 260-271.	3.4	7
2	Benefit for single-agent adjuvant chemotherapy in elderly patients with locally advanced gastric adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2022, , 1.	2.5	0
3	Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone. JAMA Network Open, 2022, 5, e2142093.	5.9	16
4	Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy. Clinical Lung Cancer, 2022, 23, e301-e309.	2.6	2
5	Association between timely targeted treatment and outcomes in patients with metastatic HER2â€overexpressing gastroesophageal adenocarcinoma. Cancer, 2022, , .	4.1	0
6	Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361.. Journal of Clinical Oncology, 2022, 40, 519-519.	1.6	0
7	Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States. Journal of the National Cancer Institute, 2022, 114, 571-578.	6.3	8
8	Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial Cancer Receiving Gene-Targeted Therapy. JAMA Oncology, 2022, 8, 1070.	7.1	2
9	Association between state Medicaid policies and accrual of Black participants to cancer clinical trials.. Journal of Clinical Oncology, 2022, 40, 1501-1501.	1.6	1
10	Saving TIME: Accuracy of a text intervention to minimize the time burden of cancer care.. Journal of Clinical Oncology, 2022, 40, 6527-6527.	1.6	0
11	Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 2082-2092.e10.	4.4	5
12	Digoxin use is associated with pancreatic cancer risk but does not affect survival. Cancer Causes and Control, 2021, 32, 41-46.	1.8	1
13	Surveillance of postchemotherapy subcentimeter residual retroperitoneal mass in metastatic nonseminomatous germ cell tumor: Does how you measure matter?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 136.e11-136.e17.	1.6	3
14	Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science, 2021, 371, 602-609.	12.6	784
15	Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1â€“positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States. Clinical Genitourinary Cancer, 2021, 19, e17-e30.	1.9	14
16	Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma. Oncologist, 2021, 26, e111-e114.	3.7	1
17	Bias reduction methods for propensity scores estimated from error-prone EHR-derived covariates. Health Services and Outcomes Research Methodology, 2021, 21, 169-187.	1.8	3
18	Rates of COVID-19â€“Related Outcomes in Cancer Compared With Noncancer Patients. JNCI Cancer Spectrum, 2021, 5, pkaa120.	2.9	26

#	Article	IF	Citations
19	Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic ATM Alterations. JNCI Cancer Spectrum, 2021, 5, pkaa121.	2.9	10
20	A clinical prediction model to assess risk for pancreatic cancer among patients with prediabetes. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, 33-38.	1.6	16
21	Association Between Statin Use at the Time of Intra-abdominal Surgery and Postoperative Adhesion-Related Complications and Small-Bowel Obstruction. JAMA Network Open, 2021, 4, e2036315.	5.9	14
22	Adherence to and determinants of guidelineâ€recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: Insights from routine practice. Cancer, 2021, 127, 2562-2570.	4.1	2
23	'Considering the totality of evidence: Combining realâ€world data with clinical trial results to better inform decisionâ€making. Pharmacoepidemiology and Drug Safety, 2021, 30, 814-816.	1.9	2
24	CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nature Medicine, 2021, 27, 1280-1289.	30.7	365
25	SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy. JCO Oncology Practice, 2021, 17, e1879-e1886.	2.9	2
26	Comparative Effectiveness of Total Neoadjuvant Therapy Versus Standard Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. Clinical Colorectal Cancer, 2021, 20, 121-129.	2.3	6
27	Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitorâ€“Based Therapy in Patients With Advanced Nonâ€“Small-Cell Lung Cancer. JAMA Oncology, 2021, 7, 937.	7.1	48
28	Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 931-945.	10.7	337
29	Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers. JAMA Oncology, 2021, 7, 1843.	7.1	26
30	Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden. European Urology Oncology, 2020, 3, 663-670.	5.4	10
31	Inflammatory Bowel Diseases Are Associated With an Increased Risk for Chronic Kidney Disease, Which Decreases With Age. Clinical Gastroenterology and Hepatology, 2020, 18, 2262-2268.	4.4	31
32	First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis. Future Oncology, 2020, 16, 4341-4345.	2.4	10
33	Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. Journal of Crohn's and Colitis, 2020, 14, 575-587.	1.3	7
34	Geographical affiliation with top 10 NIH-funded academic medical centers and differences between mortality from cardiovascular disease and cancer. American Heart Journal, 2020, 230, 54-58.	2.7	1
35	Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018. JAMA Network Open, 2020, 3, e2018318.	5.9	18
36	The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. Journal of Medical Economics, 2020, 23, 967-977.	2.1	13

#	Article	IF	Citations
37	Association Between US Administration Endorsement of Hydroxychloroquine for COVID-19 and Outpatient Prescribing. Journal of General Internal Medicine, 2020, 35, 2826-2828.	2.6	5
38	Assessing the effects of betaâ€blockers on pancreatic cancer risk: A nested caseâ€control study. Pharmacoepidemiology and Drug Safety, 2020, 29, 599-604.	1.9	13
39	Association of Medicaid Expansion Under the Affordable Care Act With Insurance Status, Cancer Stage, and Timely Treatment Among Patients With Breast, Colon, and Lung Cancer. JAMA Network Open, 2020, 3, e1921653.	5.9	97
40	Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer. European Urology, 2019, 76, 524-532.	1.9	38
41	Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer. JAMA - Journal of the American Medical Association, 2019, 322, 1209.	7.4	20
42	Locally advanced rectal adenocarcinoma: Are preoperative short and long course radiotherapy truly equivalent?. Molecular and Clinical Oncology, 2019, 10, 555-559.	1.0	2
43	Survival Benefit Persists With Delayed Initiation of Adjuvant Chemotherapy Following Radical Cystectomy for Locally Advanced Bladder Cancer. Urology, 2019, 132, 143-149.	1.0	3
44	Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer. Cancer Medicine, 2019, 8, 3698-3709.	2.8	12
45	Postoperative Radiation for Pathologic Stage T4 Colon Cancers Receiving Adjuvant Chemotherapy. Clinical Colorectal Cancer, 2019, 18, 226-230.e2.	2.3	7
46	Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice. Oncologist, 2019, 24, e397-e399.	3.7	33
47	Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma. Oncologist, 2019, 24, e671-e676.	3.7	5
48	Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma. Melanoma Research, 2019, 29, 318-321.	1.2	15
49	Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer. Oncologist, 2019, 24, 688-690.	3.7	15
50	Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. Journal of the National Cancer Institute, 2019, 111, 490-497.	6.3	69
51	Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2019, 25, 925-936.	1.9	11
52	Association between age and sex and mortality after adjuvant therapy for renal cancer. Cancer, 2019, 125, 1637-1644.	4.1	11
53	Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data. Cancer, 2019, 125, 406-415.	4.1	26
54	Total Serum Cholesterol and Pancreatic Cancer: A Nested Caseâ€“Control Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 363-369.	2.5	23

#	Article	IF	Citations
55	Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer. European Journal of Cancer, 2018, 94, 1-5.	2.8	31
56	Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. Annals of the Rheumatic Diseases, 2018, 77, 1012-1016.	0.9	48
57	Medication class enrichment analysis: a novel algorithm to analyze multiple pharmacologic exposures simultaneously using electronic health record data. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 780-789.	4.4	3
58	Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-Î±-Directed Therapy for Inflammatory Bowel Disease. American Journal of Gastroenterology, 2018, 113, 405-417.	0.4	99
59	Association Between Symptomatic Versus Asymptomatic Recurrence and Survival in Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 235-239.	1.9	7
60	Associations Between Travel Distance, Hospital Volume, and Outcomes Following Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer. Urology, 2018, 114, 87-94.	1.0	36
61	Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization. Inflammatory Bowel Diseases, 2018, 24, 217-226.	1.9	9
62	A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classificationâ€"Defining novel predictive and prognostic markers in stage III colon cancer. European Journal of Cancer, 2018, 96, 105-110.	2.8	5
63	Disparities in resection of hepatic metastases in colon cancer. Journal of Gastrointestinal Oncology, 2018, 9, 126-134.	1.4	9
64	Posttraumatic Stress Disorder and Cancer Risk: A Nested Caseâ€Control Study. Journal of Traumatic Stress, 2018, 31, 919-926.	1.8	5
65	Incidence, Risk Factors, and Clinical Effects of Recurrent Diverticular Hemorrhage: A Large Cohort Study. Gastroenterology, 2018, 155, 1416-1427.	1.3	19
66	Radiomics-guided therapy for bladder cancer: Using an optimal biomarker approach to determine extent of bladder cancer invasion from t2-weighted magnetic resonance images. Advances in Radiation Oncology, 2018, 3, 331-338.	1.2	14
67	Functional imaging of the interaction between gut microbiota and the human host: A proof-of-concept clinical study evaluating novel use for 18F-FDG PET-CT. PLoS ONE, 2018, 13, e0192747.	2.5	19
68	The Association between Age-Related Macular Degeneration and Renal Cell Carcinoma: A Nested Caseâ€"Control Study. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 743-747.	2.5	4
69	A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes. Gastroenterology, 2017, 152, 840-850.e3.	1.3	133
70	Neutrophilâ€toâ€lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer, 2017, 123, 794-801.	4.1	51
71	Impact of metformin on the progression of MGUS to multiple myeloma. Leukemia and Lymphoma, 2017, 58, 1265-1267.	1.3	20
72	A validation of clinical data captured from a novel Cancer Care Quality Program directly integrated with administrative claims data. Journal of Pragmatic and Observational Research, 2017, Volume 8, 149-155.	1.5	12

#	Article	IF	Citations
73	Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. Journal of Clinical Oncology, 2017, 35, 3575-3581.	1.6	76
74	Disentangling the Association between Statins, Cholesterol, and Colorectal Cancer: A Nested Case-Control Study. PLoS Medicine, 2016, 13, e1002007.	8.4	55
75	Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States. Annals of Surgery, 2016, 263, 298-305.	4.2	25
76	Increasing use of prescription drugs in the United Kingdom. Pharmacoepidemiology and Drug Safety, 2016, 25, 628-636.	1.9	35
77	Reappraisal of risk factors for monoclonal gammopathy of undetermined significance. American Journal of Hematology, 2016, 91, 581-584.	4.1	16
78	Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study. Arthritis and Rheumatology, 2016, 68, 2403-2411.	5.6	36
79	Cancer Recurrence Following Immune-Suppressive Therapies inÂPatients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. Gastroenterology, 2016, 151, 97-109.e4.	1.3	120
80	Serum glucose and hemoglobin A1C levels at cancer diagnosis and disease outcome. European Journal of Cancer, 2016, 59, 90-98.	2.8	19
81	Parkinsonâ€™s disease and colorectal cancer riskâ€”A nested case control study. Cancer Epidemiology, 2016, 43, 9-14.	1.9	20
82	Multimodality Therapy Improves Survival in Resected Early Stage Gastric Cancer in the United States. Annals of Surgical Oncology, 2016, 23, 2936-2945.	1.5	19
83	Pernicious anemia and colorectal cancer risk â€“ A nested caseâ€“control study. Digestive and Liver Disease, 2016, 48, 1386-1390.	0.9	7
84	Ion channel blockers and glioblastoma risk and outcome: a nested caseâ€“control and retrospective cohort studies. Pharmacoepidemiology and Drug Safety, 2016, 25, 1179-1185.	1.9	1
85	An association between newly diagnosed cutaneous T cell lymphoma and prior impetigo: a nested caseâ€“control study. Archives of Dermatological Research, 2016, 308, 661-664.	1.9	2
86	Validation of a coding algorithm for intra-abdominal surgeries and adhesion-related complications in an electronic medical records database. Pharmacoepidemiology and Drug Safety, 2016, 25, 405-412.	1.9	4
87	Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: A propensity scoreâ€“matched analysis. Cancer, 2016, 122, 693-701.	4.1	87
88	Liver transplant center variability in accepting organ offers and its impact on patient survival. Journal of Hepatology, 2016, 64, 843-851.	3.7	62
89	Administration of Antibiotics to Children Before Age 2 Years Increases Risk for Childhood Obesity. Gastroenterology, 2016, 151, 120-129.e5.	1.3	145
90	Association of Itraconazole, a Hedgehog Inhibitor, and Bladder Cancer. Journal of Urology, 2016, 196, 343-348.	0.4	9

#	Article	IF	Citations
91	A Risk Prediction Model for Sporadic CRC Based on Routine Lab Results. Digestive Diseases and Sciences, 2016, 61, 2076-2086.	2.3	11
92	Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. JAMA Dermatology, 2016, 152, 164.	4.1	131
93	Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer. Cancer Research and Treatment, 2016, 48, 1084-1091.	3.0	15
94	Dr Lurie and Colleagues Reply. Journal of Clinical Psychiatry, 2016, 77, e1654-e1654.	2.2	0
95	Omission of Adjuvant Therapy After Gastric Cancer Resection: Development of a Validated Risk Model. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 531-541.	4.9	18
96	Adjuvant Radiation Therapy Treatment Time Impacts Overall Survival in Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 326-336.	0.8	15
97	The effect of past antibiotic exposure on diabetes risk. European Journal of Endocrinology, 2015, 172, 639-648.	3.7	131
98	The Benefit-to-Risk Balance of Combining Infliximab With Azathioprine Varies With Age: A Markov Model. Clinical Gastroenterology and Hepatology, 2015, 13, 302-309.e11.	4.4	35
99	Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. JAMA - Journal of the American Medical Association, 2015, 314, 265.	7.4	263
100	Angiosarcoma of the Bladder Following Prostate Radiotherapy. American Journal of Medicine, 2015, 128, e11-e12.	1.5	7
101	Thyroid Dysfunction, Thyroid Hormone Replacement and Colorectal Cancer Risk. Journal of the National Cancer Institute, 2015, 107, djv084.	6.3	46
102	Impact of antibiotic exposure on the risk of colorectal cancer. Pharmacoepidemiology and Drug Safety, 2015, 24, 534-542.	1.9	73
103	Validation of a Coding Algorithm to Identify Bladder Cancer and Distinguish Stage in an Electronic Medical Records Database. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 303-307.	2.5	15
104	Anti-depressant therapy and cancer risk: A nested case-control study. European Neuropsychopharmacology, 2015, 25, 1147-1157.	0.7	21
105	Multimodality Treatment of T4 Gastric Cancer in the United States: Utilization Trends and Impact on Survival. Annals of Surgical Oncology, 2015, 22, 863-872.	1.5	15
106	Recurrent antibiotic exposure may promote cancer formation â€“ Another step in understanding the role of the human microbiota?. European Journal of Cancer, 2015, 51, 2655-2664.	2.8	233
107	Antibiotic Exposure and the Risk for Depression, Anxiety, or Psychosis. Journal of Clinical Psychiatry, 2015, 76, 1522-1528.	2.2	169
108	Digoxin use and the risk for colorectal cancer. Pharmacoepidemiology and Drug Safety, 2014, 23, 1147-1153.	1.9	17

#	Article	IF	Citations
109	Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. Pharmacoepidemiology and Drug Safety, 2014, 23, 636-645.	1.9	26
110	Distinguishing incident and prevalent diabetes in an electronic medical records database. Pharmacoepidemiology and Drug Safety, 2014, 23, 111-118.	1.9	23
111	Implications of inadequate lymph node staging in resectable gastric cancer: A contemporary analysis using the <scp>N</scp>ational <scp>C</scp>ancer <scp>D</scp>ata <scp>B</scp>ase. Cancer, 2014, 120, 2855-2865.	4.1	54
112	Height as an independent anthropomorphic risk factor for colorectal cancer. European Journal of Gastroenterology and Hepatology, 2014, 26, 1422-1427.	1.6	8
113	Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas. Diabetes Care, 2014, 37, 1910-1917.	8.6	64
114	Association Between Longer Therapy With Thiazolidinediones and Risk of Bladder Cancer: A Cohort Study. Journal of the National Cancer Institute, 2012, 104, 1411-1421.	6.3	105
115	Granulomatosis and Testicular Germ Cell Tumors. Urology, 2012, 80, 1303-1306.	1.0	6
116	Long-term therapy with thiazolidinediones and the risk of bladder cancer: A cohort study.. Journal of Clinical Oncology, 2012, 30, 1503-1503.	1.6	3
117	Vinflunine in the treatment of advanced bladder cancer. Expert Review of Anticancer Therapy, 2011, 11, 13-20.	2.4	11
118	Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood, 2009, 113, 4834-4840.	1.4	829
119	Ayurveda and yoga in cardiovascular diseases. Cardiology in Review, 2005, 13, 155-62.	1.4	8